[Long-acting injection - four-times-a-year. Review of the 3-monthly paliperidone-palmitate injection].
Continuous maintenance antipsychotic treatment is one of the most important factor in the long-term course of schizophrenia. Among the therapeutic options available today, the long-acting injectable antipsychotics are those that are able to efficiently provide an optimal treatment strategy required for continuous maintenance treatment. Three-monthly paliperidone palmitate (TREVICTA) is an important milestone in this therapeutic approach, since it is the first and only antipsychotic treatment for patients with schizophrenia, which provides the yearly maintenance therapeutic dose by four injections. Clinical studies have shown that compared to the placebo, TREVICTA significantly delays time to relapse, reduces relapse rate, and its effect is equivalent to the well-known monthly paliperidone palmitate. Data on safety have revealed that TREVICTA was well tolerated and safe, and the rare side effects were consistent with that of paliperidone previously described. In conclusion, TREVICTA is a new and unique treatment option for patients who respond well to paliperidone treatment.